Progress in EBV Vaccines
The Epstein-Barr virus (EBV) is a ubiquitous pathogen that imparts a significant burden of disease on the human population. EBV is the primary cause of infectious mononucleosis and is etiologically linked to the development of numerous malignancies. In recent years, evidence has also been amassed th...
Main Authors: | Dwain G. van Zyl, Josef Mautner, Henri-Jacques Delecluse |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2019-02-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fonc.2019.00104/full |
Similar Items
-
Immunogenic particles with a broad antigenic spectrum stimulate cytolytic T cells and offer increased protection against EBV infection ex vivo and in mice.
by: Dwain G van Zyl, et al.
Published: (2018-12-01) -
Immunoinformatic Analysis Reveals Antigenic Heterogeneity of Epstein-Barr Virus Is Immune-Driven
by: Ana Cirac, et al.
Published: (2021-12-01) -
Editorial: EBV-induced T cell immunity in cancers
by: Baochun Zhang, et al.
Published: (2024-07-01) -
Age and Epstein-Barr viral load at diagnosis of post-transplant lymphoproliferative disease are associated with patient survival in kidney transplant recipients
by: Diogo Francisco, et al.
Published: (2024-09-01) -
Prophylactic and Therapeutic EBV Vaccines: Major Scientific Obstacles, Historical Progress, and Future Direction
by: Jing Cai, et al.
Published: (2021-11-01)